Patents by Inventor Masahiro Neya

Masahiro Neya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190284228
    Abstract: Provided are: a compound represented by formula (I); a retinoid metabolic pathway inhibitor comprising the same; an agent for increasing the ratio of memory T cells; a prophylactic and/or therapeutic agent for cancer or an infectious disease; a cancer immunotherapeutic adjuvant; an immunopotentiator; and a method for preparing a T cell population wherein the ratio of memory T cells is increased, said method comprising using the compound of formula (I).
    Type: Application
    Filed: November 8, 2017
    Publication date: September 19, 2019
    Applicants: OSAKA UNIVERSITY, KNC LABORATORIES CO., LTD.
    Inventors: Haruo SUGIYAMA, Fumihiro FUJIKI, Masahiro NEYA, Shinya KOHNO
  • Patent number: 9771316
    Abstract: The invention provides a compound having a selective inhibitory activity against highly-expressed LAT-1 in tumor cell. The compound is represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, and a LAT-1 inhibitor comprising the same.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: September 26, 2017
    Assignees: Osaka University, KNC Laboratories Co., Ltd.
    Inventors: Yoshikatsu Kanai, Shushi Nagamori, Yoshihiko Kitaura, Masahiro Neya, Naohiro Matsushita
  • Publication number: 20150336876
    Abstract: The invention provides a compound having a selective inhibitory activity against highly-expressed LAT-1 in tumor cell. The compound is represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, and a LAT-1 inhibitor comprising the same.
    Type: Application
    Filed: January 21, 2014
    Publication date: November 26, 2015
    Inventors: Yoshikatsu KANAI, Shushi NAGAMORI, Yoshihiko KITAURA, Masahiro NEYA, Naohiro MATSUSHITA
  • Patent number: 9056862
    Abstract: The present invention provides an anticancer drug having a Ras function inhibitory action. The present invention provides a Ras function inhibitor comprising a compound represented by the formula (I?): wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: June 16, 2015
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, KNC LABORATORIES CO., LTD.
    Inventors: Tohru Kataoka, Fumi Shima, Masahiro Neya, Daisuke Sasahara
  • Patent number: 8802679
    Abstract: Compounds of formula (I) defined herein exhibit VAP-1 inhibitory activity, and as a result, are useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: August 12, 2014
    Assignee: Astellas Pharma Inc.
    Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Yuji Koga, Norio Seki, Jiro Fujiyasu, Masahiro Neya
  • Publication number: 20140194412
    Abstract: The present invention provides an anticancer drug having a Ras function inhibitory action. The present invention provides a Ras function inhibitor comprising a compound represented by the formula (I?): wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Application
    Filed: May 9, 2012
    Publication date: July 10, 2014
    Applicants: KNC LABORATORIES CO., LTD., NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
    Inventors: Tohru Kataoka, Fumi Shima, Masahiro Neya, Daisuke Sasahara
  • Patent number: 8252895
    Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: August 28, 2012
    Assignee: Astellas Pharma Inc.
    Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
  • Publication number: 20120184520
    Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.
    Type: Application
    Filed: September 15, 2010
    Publication date: July 19, 2012
    Applicant: Astellas Pharma Inc.
    Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Yuji Koga, Norio Seki, Jiro Fujiyasu, Masahiro Neya
  • Patent number: 7872097
    Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: January 18, 2011
    Assignee: Astellas Pharma Inc.
    Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
  • Publication number: 20100286033
    Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.
    Type: Application
    Filed: July 21, 2010
    Publication date: November 11, 2010
    Inventors: Masahiro NEYA, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
  • Publication number: 20090170755
    Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.
    Type: Application
    Filed: October 26, 2006
    Publication date: July 2, 2009
    Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
  • Patent number: 6967197
    Abstract: A compound of formula (I) in which R1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R2 is amidated carboxy, R3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor ? (TNF ?)
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: November 22, 2005
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Masahiro Neya, Hitoshi Yamazaki, Kazuhiko Ohne, Yuki Sawada, Tsuyoshi Mizutani, Yoshimasa Imamura, Noriko Mukai
  • Publication number: 20040266826
    Abstract: A compound of the formula: in which R1 is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted bicyclic heterocyclic group, optionally substituted lower alkenyl or optionally substituted lower alkynyl, and R2 is carboxy or protected carboxy, or a salt thereof, useful for treating and/or preventing MMP- or TNF-&agr; mediated diseases.
    Type: Application
    Filed: February 27, 2004
    Publication date: December 30, 2004
    Inventors: Masahiro Neya, Akihiko Sawada, Kazuhiko Ohne, Yoshito Abe, Tsuyoshi Mizutani, Naoki Ishibashi, Makoto Inoue
  • Publication number: 20030134849
    Abstract: A compound of formula (I) in which R1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R2 is amidated carboxy, R3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor &agr; (TNF &agr;).
    Type: Application
    Filed: August 19, 2002
    Publication date: July 17, 2003
    Inventors: Masahiro Neya, Hitoshi Yamazaki, Kazuhiko Ohne, Yuki Sawada, Tsuyoshi Mizutani, Yoshimasa Imamura, Noriko Mukai
  • Publication number: 20030060473
    Abstract: A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R1 is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R2 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R3 is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substituted lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substituted amino; R4 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R5 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R10 is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 3, 2002
    Publication date: March 27, 2003
    Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.
    Inventors: Masahiro Neya, Hitoshi Yamazaki, Natsuko Kayakiri, Kentaro Sato, Teruo Oku
  • Patent number: 6489324
    Abstract: A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R1 is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R2 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R3 is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substituted lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substituted amino; R4 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R5 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R10 is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 22, 2001
    Date of Patent: December 3, 2002
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Masahiro Neya, Hitoshi Yamazaki, Natsuko Kayakiri, Kentaro Sato, Teruo Oku
  • Publication number: 20020128270
    Abstract: A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R 1 is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R 2 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R 3 is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substitued lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substitued amino, R 4 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group, R 5 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R 10 is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 22, 2001
    Publication date: September 12, 2002
    Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.
    Inventors: Masahiro Neya, Hitoshi Yamazaki, Natsuko Kayakiri, Kentaro Sato, Teruo Oku
  • Patent number: 6333324
    Abstract: A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R1 is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R2 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R3 is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substitued lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substitued amino; R4 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R5 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R10 is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 26, 1999
    Date of Patent: December 25, 2001
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Masahiro Neya, Hitoshi Yamazaki, Natsuko Kayakiri, Kentaro Sato, Teruo Oku
  • Patent number: 6207686
    Abstract: A compound of formula (I), in which: R1 is lower alkyl, cyclo(lower)alkyl, optionally substituted aryl, optionally substituted heterocyclic group, cyclo(lower)alkyl(lower)alkyl, or ar(lower)alkyl; R2 is hydrogen, hydroxy or protected hydroxy; R3 is lower alkyl, aryl, ar(lower)alkyl or optionally substituted heterocyclic(lower)alkyl; R4 is carboxy, protected carboxy or lower alkylsufonylcarbamoyl; R5 is hydrogen or lower alkyl; R6 is hydrogen or heterocyclic group; A is a single bond or lower alkylene, and Ar is optionally substituted aryl, or pharmaceutically acceptable salts thereof, having endothelin antagonistic activity.
    Type: Grant
    Filed: June 20, 1997
    Date of Patent: March 27, 2001
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Masahiro Neya, Tatsuya Zenkoh, Hitoshi Sawada, Chiyoshi Kasahara, Masayoshi Murata, Keiji Hemmi
  • Patent number: 5888972
    Abstract: A compound of the formula: ##STR1## in which R.sup.4 is acyl,R.sup.5 is lower alkyl,R.sup.6 is optionally substituted ar(lower)alkyl or optionally substituted heterocyclic-(lower)alkyl,R.sup.7 is lower alkyl or lower alkylthio(lower)alkyl,R.sup.8 is carboxy or protected carboxy,A is lower alkylene,Z is a group of the formula: ##STR2## wherein R.sup.1 is hydrogen, lower alkyl, common amino-protective group or optionally substituted ar(lower)alkyl,R.sup.2 is hydrogen, lower alkyl, optionally substituted ar(lower)alkyl, optionally substituted heterocyclic-(lower)alkyl, optionally substituted cyclo(lower)alkyl(lower)alkyl, common amino-protective group, amino(or protected amino)(lower)alkyl, optionally substituted heterocyclic-carbonyl or cyclo(lower)alkyl, andR.sup.3 is optionally substituted heterocyclic(lower)alkyl, andm is an integer of 0 to 2,or pharmaceutically acceptable salts thereof, useful as endothelin antagonist.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: March 30, 1999
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Keiji Hemmi, deceased, Masahiro Neya, Naoki Fukami, Natsuko Kayakiri, Hirokazu Tanaka